NasdaqGS - Nasdaq Real Time Price ? USD Prelude Therapeutics Incorporated (PRLD) Follow Compare 1.7800 -0.1200 (-6.32%) At close: October 21 at 4:00 PM EDT 1.7800 0.00 (0.00%) After hours: October 21 at 5:02 PM EDT All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST)WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of three abstracts regarding its SMARCA Degrader Programs at the 36th EORTC-NCI-AACR Symposium taking GlobeNewswire ? 12 days ago PRLD -6.32% Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall PREMIUM MT Newswires ? last month PRLD -6.32% Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial - Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drug-related serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE GlobeNewswire ? last month PRLD -6.32% Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024 PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST) Prelude will host an investor webcast on September 13, 2024, 6:00 PM CEST, (12:00 PM EST) WILMINGTON, Del., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of an abstr GlobeNewswire ? last month PRLD -6.32% MSD discontinues two Phase III Keytruda trials MSD is axing two Phase III Keytruda trials after they failed to meet the primary and secondary endpoints. Clinical Trials Arena ? last month MRK GLDAF PRLD -6.32% Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in September Received investigational new drug (IND) authorization for PRT7732, its first-in-class oral SMARCA2 degrader, from the U.S. Food and Drug Administration (FDA) Announced clinical collaboration with Merck to evaluate PRT3789 in combination with Merck’s anti-PD-1 therapy KEYTRUDA? (pembrolizumab) i GlobeNewswire ? 2 months ago PRLD -6.32% We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate We can readily understand why investors are attracted to unprofitable companies. For example, although... Simply Wall St. ? 2 months ago PRLD -6.32% Prelude and MSD partner to trial PRT3789 and Keytruda combination MSD will supply KEYTRUDA for the combination trial, with Prelude acting as the sponsor. Clinical Trials Arena ? 3 months ago MRK PRLD -6.32% Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA? (pembrolizumab) in Patients with SMARCA4-Mutated Cancers Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms. Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA. WILMINGTON, Del., July 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced that it has entered into GlobeNewswire ? 3 months ago PRLD -6.32% Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls Spirit Aero downgraded, Skyworks upgraded: Wall Street's top analyst calls The Fly ? 3 months ago SWKS TRU HMST Prelude Therapeutics to Participate in Upcoming Healthcare Conferences WILMINGTON, Del., June 03, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2024:On Thursday, June 6th, at 1:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. A live webcast of the fireside chat can be accessed here. Goldman Sachs 45th Ann GlobeNewswire ? 4 months ago PRLD -6.32% Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Life Sciences Conference, taking place in New York City on May 13 and 14. On Tuesday, May 14, at 1:00 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat. A live webca GlobeNewswire ? 5 months ago PRLD -6.32% Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update First-in-class IV SMARCA2 degrader, PRT3789 and potentially best-in-class CDK9 inhibitor, PRT2527 remain on track to generate initial proof-of-concept data in 2024 New preclinical data presented at AACR 2024 included first characterization of PRT7732, a highly-selective, orally bioavailable SMARCA2 degrader Operational leadership capabilities further strengthened by recent hires Chief Business Officer Sean Brusky and Senior Vice President, Investor Relations Robert Doody Current cash runway into GlobeNewswire ? 5 months ago PRLD -6.32% Several Insiders Invested In Prelude Therapeutics Flagging Positive News It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... Simply Wall St. ? 6 months ago PRLD -6.32% Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targe GlobeNewswire ? 6 months ago PRLD -6.32% Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been acc GlobeNewswire ? 7 months ago PRLD -6.32% Prelude Therapeutics to Participate in Barclays Global Healthcare Conference WILMINGTON, Del., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays Global Healthcare Conference in Miami, March 12-14, 2024. On Wednesday, March 13, at 3:05 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat, hosted by Barclays. A live GlobeNewswire ? 7 months ago PRLD -6.32% Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... Simply Wall St. ? 7 months ago PRLD -6.32% Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024 First-in-class IV SMARCA2 degrader and potentially best-in-class CDK9 inhibitor on track to generate potential proof-of-concept data in 2024 Highly selective oral SMARCA2 degrader PRT7732 IND expected to be filed in first half and enter Phase 1 clinical trial in second half of 2024 Recently established partnership with AbCellera to jointly discover, develop, and commercialize a portfolio of next generation precision ADCs Current cash runway into 2026 with $232.9 million in cash, cash equivalents GlobeNewswire ? 8 months ago PRLD -6.32% Prelude Therapeutics Incorporated (NASDAQ:PRLD) is definitely on the radar of hedge funds investors who own 33% of the company Key Insights Given the large stake in the stock by institutions, Prelude Therapeutics' stock price might be vulnerable... Simply Wall St. ? 9 months ago PRLD -6.32% Performance Overview Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return PRLD S&P 500 YTD -58.31% +22.73% 1-Year -25.52% +38.58% 3-Year -90.08% +29.05%
